Assess whether integration costs were sandbagged in the CIM (bc1b2b)

Situation

Regulatory-approval critical-path calendar arrived with an earnout based on 'adjusted EBITDA' with no dictionary for commercial-diligence partner. That is a M&A Due Diligence Legal, IP, and Regulatory decision on integration costs were sandbagged in a cross-border deal with earnout-heavy structure.

Decision

Commercial-diligence partner in a cross-border deal with earnout-heavy structure must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after an earnout based on 'adjusted EBITDA' with no dictionary.

Hypotheses to test

• Commercial-diligence partner can defend Proceed from regulatory-approval critical-path calendar after an earnout based on 'adjusted EBITDA' with no dictionary in a M&A Due Diligence challenge.
• Commercial-diligence partner cannot defend Proceed from regulatory-approval critical-path calendar; Reprice is what the extract actually supports after an earnout based on 'adjusted EBITDA' with no dictionary.
• An earnout based on 'adjusted EBITDA' with no dictionary never reached the population in regulatory-approval critical-path calendar — reopen intake, do not close integration costs were sandbagged.
• Two facts in regulatory-approval critical-path calendar after an earnout based on 'adjusted EBITDA' with no dictionary conflict for commercial-diligence partner; hold this Legal, IP, and Regulatory file.

Analysis required

• Name the document commercial-diligence partner still needs before signing.
• Test whether an earnout based on 'adjusted EBITDA' with no dictionary is a diligence gap, a price chip, or a walk-away.
• Separate a one-off add-back from a recurring earnings issue in regulatory-approval critical-path calendar.
• For this M&A Due Diligence Legal, IP, and Regulatory file, read regulatory-approval critical-path calendar against an earnout based on 'adjusted EBITDA' with no dictionary and write the one fact that would move integration costs were sandbagged for commercial-diligence partner.

Recommendation

Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Legal, IP, and Regulatory packet (regulatory-approval critical-path calendar after an earnout based on 'adjusted EBITDA' with no dictionary). Lead with the M&A Due Diligence option regulatory-approval critical-path calendar can support after an earnout based on 'adjusted EBITDA' with no dictionary, then the two facts that force it, then the Monday action for commercial-diligence partner in a cross-border deal with earnout-heavy structure.